NCT01120314View on ClinicalTrials.gov

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Renal Impairment
Interventions
DRUG

OTAMIXABAN (XRP0673)

"Form: solution for injection~Route: intravenous"

Trial Locations (4)

32806

Investigational Site Number 840005, Orlando

33169

Investigational Site Number 840003, Miami Gardens

37920

Investigational Site Number 840002, Knoxville

55144

Investigational Site Number 840004, Saint Paul

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY